IRBESARTAN RELATED COMPOUND A (25 MG) (1-PENTANOYLAMINO-CYCLOPENTANECARBOXYLIC ACID [2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMIDE)
IRBESARTAN RELATED COMPOUND A (25 MG) (1-PENTANOYLAMINO-CYCLOPENTANECARBOXYLIC ACID [2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMIDE) 物理性質
- 比重(密度) :
- 1.26
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- DMSO (Slightly), Methanol (Slightly)
- 酸解離定数(Pka):
- 4.16±0.10(Predicted)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
呼吸器への刺激のおそれ |
特定標的臓器毒性、単回暴露； 気道刺激性 |
3 |
警告 |
|
|
|
| 注意書き |
| P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
| P301+P312 |
飲み込んだ場合：気分が悪い時は医師に連絡する こと。 |
| P302+P352 |
皮膚に付着した場合：多量の水と石鹸で洗うこと。 |
| P305+P351+P338 |
眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
IRBESARTAN RELATED COMPOUND A (25 MG) (1-PENTANOYLAMINO-CYCLOPENTANECARBOXYLIC ACID [2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMIDE) 価格
もっと(6)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCO859980 |
1-[(1-Oxopentyl)amino]-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-cyclopentanecarboxamide |
748812-53-5 |
5mg |
￥65100 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCO859980 |
1-[(1-Oxopentyl)amino]-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-cyclopentanecarboxamide |
748812-53-5 |
50mg |
￥507600 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
PHR1958 |
Pharmaceutical Secondary Standard; Certified Reference Material
Irbesartan Related Compound A Pharmaceutical Secondary Standard; Certified Reference Material |
748812-53-5 |
50mg |
￥108000 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
1347711 |
United States Pharmacopeia (USP) Reference Standard
Irbesartan Related Compound A United States Pharmacopeia (USP) Reference Standard |
748812-53-5 |
25mg |
￥176000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01USP1347711 |
Irbesartan Related Compound A (1-pentanoylamino-cyclopentanecarboxylic acid [2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amide)
Irbesartan Related Compound A (1-pentanoylamino-cyclopentanecarboxylic acid [2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amide) |
748812-53-5 |
25mg |
￥289100 |
2024-03-01 |
購入 |
IRBESARTAN RELATED COMPOUND A (25 MG) (1-PENTANOYLAMINO-CYCLOPENTANECARBOXYLIC ACID [2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMIDE) 化学特性,用途語,生産方法
使用
1-[(1-Oxopentyl)amino]-N-[[2''-(2H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl]-cyclopentanecarboxamide (Irbesartan EP Impurity A; Irbesartan USP Related Compound A; Irbesartan Metabolite) is a metabolite of Irbesartan (I751000), an angiotensin II type 1 (AII1)-receptor antagonist.
IRBESARTAN RELATED COMPOUND A (25 MG) (1-PENTANOYLAMINO-CYCLOPENTANECARBOXYLIC ACID [2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMIDE) 上流と下流の製品情報
原材料
準備製品
IRBESARTAN RELATED COMPOUND A (25 MG) (1-PENTANOYLAMINO-CYCLOPENTANECARBOXYLIC ACID [2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMIDE) 生産企業
Global( 73)Suppliers
748812-53-5()キーワード:
- 748812-53-5
- N-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1-pentanamidocyclopentanecarboxamide
- N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1-pentanamidocyclopentanecarboxamide
- Irbesartan Related Compound A (25 mg) (1-pentanoylaminocyclopentanecarboxylic acid [2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amide)
- Irbesartan Related CoMpound A(1-pentanoylaMino-cyclopentanecarboxylic acid [2'-(1H-tetrazol-5-yl)-biphenyl-4-ylMethyl]-aMide)
- 1-[(1-Oxopentyl)amino]-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]cyclopentanecarboxamide
- rbesartan EP IMp A (USP R C A)
- AOBO-287 Irbesartan Related CoMpound A(1-pentanoyl...
- Irbesartan Impurity I(1-(pentanoylamino)-N-[[2-(1H-tetrazol -5-yl)biphenyl-4-yl]methyl]cyclopentanecarboxamide)
- N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1-pentanamidocyclopentane-1-carboxamide
- 1-(pentanoylamino)-N-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]cyclopentane-1-carboxamide
- Irbesartan ImpurityI (1-pentanoylamino-cyclopentanecarboxylic acid [2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amide)
- Irbesartan EP Impurity A
- Irbesartan impurity A (EP)
- Irbesartan Impurity 1(Irbesartan EP Impurity A)
- Cyclopentanecarboxamide, 1-[(1-oxopentyl)amino]-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- Irbesartan Impurity 1（EP Impurity A）
- Irbesartan Impurity I
- Irbesartan EP Impurity A/ Irbesartan Related Compound A
- Irbesartan EP Impurity AQ: What is
Irbesartan EP Impurity A Q: What is the CAS Number of
Irbesartan EP Impurity A Q: What is the storage condition of
Irbesartan EP Impurity A Q: What are the applications of
Irbesartan EP Impurity A
- Irbesartan Related Compound A (1-pentanoylamino-cyclopentanecarboxylic acid [2''-(1H-tetrazol-5-yl)- (1347711)
- Irbesartan USP Related Compound A
- Irbesartan EP Impurity A
Irbesartan USP Related Compound A
- 1-(Pentanoylamino)-N-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]cyclopentanecarboxamide
- IRBESARTAN RELATED COMPOUND A (25 MG) (1-PENTANOYLAMINO-CYCLOPENTANECARBOXYLIC ACID [2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMIDE)